Nabriva Therapeutics plc (NBRV) financial statements (2022 and earlier)

Company profile

Business Address 25-28 NORTH WALL QUAY
DUBLIN, D01 H104
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:47,90052,20061,30055,00041,60041,40050,100
Cash and cash equivalents47,65951,99561,14054,78841,35941,12249,660
Short-term investments161616161616175
Other undisclosed cash, cash equivalents, and short-term investments225189144196225262265
Receivables9,321   175  
Inventory, net of allowances, customer advances and progress billings14,50915,58110,1138,9745,8235,8035,196
Inventory14,50915,58110,1138,9745,8235,8035,196
Prepaid expense5,1555,60911,59510,2255,8803,7543,921
Other undisclosed current assets3,38015,02211,6124,2403,7403,3533,192
Total current assets:80,26588,41294,62078,43957,21854,31062,409
Noncurrent Assets
Nontrade receivables    370369368
Property, plant and equipment2332893555217682,0072,176
Intangible assets, net (including goodwill)31415465808497
Intangible assets, net (excluding goodwill)31415465808497
Other noncurrent assets380380380383   
Total noncurrent assets:6447107899691,2182,4602,641
TOTAL ASSETS:80,90989,12295,40979,40858,43656,77065,050
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities18,20116,57016,82514,92815,73310,97510,996
Accounts payable4,3721,4761,5823,6362,8892,0412,620
Accrued liabilities13,82915,09415,24311,29212,8448,9348,376
Deferred revenue374375563750750  
Debt3,7652,7801,8232,6212,041  
Total current liabilities:22,34019,72519,21118,29918,52410,97510,996
Noncurrent Liabilities
Long-term debt and lease obligation4,2655,1696,0465,1775,6867,6107,477
Long-term debt, excluding current maturities4,2655,1696,0465,1775,6867,6107,477
Liabilities, other than long-term debt9549389519411,0911,9562,116
Other liabilities9549389519411,0911,9562,116
Total noncurrent liabilities:5,2196,1076,9976,1186,7779,5669,593
Total liabilities:27,55925,83226,20824,41725,30120,54120,589
Stockholders' equity
Stockholders' equity attributable to parent53,35063,29069,20154,99133,13536,22944,461
Common stock5675434973542111,5001,430
Additional paid in capital648,432645,333640,638614,817579,123563,095558,446
Accumulated other comprehensive income27272727272727
Accumulated deficit(595,676)(582,613)(571,961)(560,207)(546,226)(528,393)(515,442)
Total stockholders' equity:53,35063,29069,20154,99133,13536,22944,461
TOTAL LIABILITIES AND EQUITY:80,90989,12295,40979,40858,43656,77065,050

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues9,2618,8628,2432,5292,4601,291487
Cost of revenue(5,266)(4,199)(3,621)(62)(365)(25)(368)
Cost of goods and services sold  (3,621)(62)(365)(25)(368)
Gross profit:3,9954,6634,6222,4672,0951,266119
Operating expenses(16,879)(15,477)(16,004)(15,915)(20,363)(14,483)(14,572)
Operating loss:(12,884)(10,814)(11,382)(13,448)(18,268)(13,217)(14,453)
Nonoperating income (expense)(10)131475(121)574455(618)
Other nonoperating income (expense)(10)131470(122)573450(634)
Interest and debt expense(223)(221)(241)(222)(199)(261)(251)
Loss from continuing operations before income taxes:(13,117)(10,904)(11,148)(13,791)(17,893)(13,023)(15,322)
Income tax expense (benefit)54252(606)(190)6072(119)
Net loss available to common stockholders, diluted:(13,063)(10,652)(11,754)(13,981)(17,833)(12,951)(15,441)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(13,063)(10,652)(11,754)(13,981)(17,833)(12,951)(15,441)
Comprehensive loss, net of tax, attributable to parent:(13,063)(10,652)(11,754)(13,981)(17,833)(12,951)(15,441)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: